The Neuro-Oncology Program has been an Established Research Program since 2005. The Program is led by a basic scientist, C. Stiles(DFCI), and a clinician, R. Martuza(MGH), both of whom bring years of leadership experience to their respective roles. The central focus of the Neuro-Oncology Program has been high grade-glioma in adults. The Program has a clinical trials portfolio that offers a range of therapeutic modalities for glioma, including: radiation, tumor vaccines, oncolytic viruses and signal transduction inhibitors. There are also two signal transduction pathways identified as areas of priority: VEGF antagonists and PI3K antagonists. Pediatric neuro-oncology is a growing area of interest. Genetically simple tumors of children have historically shed light on more common, genetically complex adult tumors. One of the significant strengths of the Neuro-Oncology Program in this regard is the presence of a strong pediatric oncology program anchored at DFCI for outpatient care and CHB, a nationally recognized pediatric hospital, for inpatient services, creating a unified pediatric oncology facility that has spanned both institutions for decades. Over the next five years, a goal is to move recent genetic insights from the bench to the bedside in order to improve the standard of clinical care and enable genetically-informed clinical trials. The Program plans to develop CLIA-certified assays for all "actionable" genetic lesions in high-grade glioma and to apply these assays to every tumor resected at DF/HCC hospitals. There are 93 members in the Program drawn from all seven DF/HCC member institutions. They represent 13 departments of HMS and one department of HSPH. Collectively, members receive over $22.6 million in cancer-relevant funding, of which $8.1 million was from NCI and $10 million was from other peer-reviewed sponsors. During the project period (2006 to 2010), members published 997 articles in peer-reviewed journals, of which 18% were intra-programmatic, 33% were inter-programmatic, and 21% were interinstitutional. At the time of the CCSG renewal in 2005, the Program received a merit score of "excellent to very good".
High-grade gliomas in adult patients are generally incurable. Collectively, these tumors are the third leading cause of cancer-related death among middle-aged men and the fourth leading cause of death for women between the ages of 15 and 34. The goal of the Neuro-Oncology Program is to improve the standard of care for patients with these tumors through genetically informed clinical trials (a.k.a. personalized medicine) conducted on a new generation of targeted therapeutics (a.k.a. smart drugs).
|Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33|
|Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:|
|Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192|
|Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95|
|Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9|
|Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57|
|Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49|
|Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90|
|Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80|
|Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608|
Showing the most recent 10 out of 177 publications